Document Detail

Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
MedLine Citation:
PMID:  19778669     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We used a U.S. model of health care costs to examine the cost effectiveness of enoxaparin compared with unfractionated heparin (UFH) as adjunctive therapy for fibrinolysis in patients with ST-segment elevation myocardial infarction (STEMI). BACKGROUND: The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study, a large, randomized, multinational trial, demonstrated a reduction in death or nonfatal myocardial infarction when enoxaparin was used instead of UFH as adjunctive therapy for fibrinolysis in patients with STEMI. METHODS: We used patient-level clinical outcomes and resource use from the ExTRACT-TIMI 25 trial and estimates of life expectancy gains as a result of the prevention of the clinical events on the basis of the Framingham Heart Study. RESULTS: Index hospitalization costs trended lower by $126 in the enoxaparin group (95% confidence interval [CI]: -$295 to $49). Thirty-day costs trended higher by $102 for enoxaparin (95% CI: $108 to $314). Patients receiving enoxaparin gained an average of 0.12 life-years relative to patients given UFH. Estimated total lifetime costs were $1,207 higher in the enoxaparin group (95% CI: $491 to $1,923). The incremental cost-effectiveness ratio of enoxaparin compared with UFH was $5,700 per life-year gained, with 99.9% of bootstrap-derived estimates <$50,000 per life-year gained. Using a probabilistic sensitivity analysis, there is a 90% probability that enoxaparin is cost effective for lifetime, provided that the willingness-to-pay value exceeds $50,000. CONCLUSIONS: Based on a U.S. model of health care economics, the strategy of using enoxaparin instead of UFH as adjunctive therapy for fibrinolysis in patients with STEMI is cost effective according to commonly used benchmarks.
Leo Marcoff; Zugui Zhang; Wei Zhang; Edward Ewen; Claudine Jurkovitz; Prisca Leguet; Paul Kolm; William S Weintraub
Related Documents :
12082199 - Bleeding complications of platelet glycoprotein iib/iiia inhibitor abciximab (reopro ).
21060749 - Clinical benefit of low molecular weight heparin for st-segment elevation myocardial in...
11096509 - Unstable angina.
19530369 - The role of low-molecular-weight heparins in the management of unstable angina and non-...
18086929 - Initial aspirin dose and outcome among st-elevation myocardial infarction patients trea...
20948699 - Intensity of antiplatelet therapy and percutaneous coronary intervention.
1544079 - Rates of cardiac catheterization, coronary angioplasty and open-heart surgery in adults...
2113089 - Coronary vascular reactivity after heart transplantation in dogs: nitroglycerin-induced...
21635989 - Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasu...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  54     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-25     Completed Date:  2009-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1271-9     Citation Subset:  AIM; IM    
Christiana Care Center for Outcomes Research, Christiana Care Health System, Newark, Delaware 19718, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cost-Benefit Analysis
Double-Blind Method
Enoxaparin / economics*,  therapeutic use
Fibrinolytic Agents / economics*,  therapeutic use
Heparin / economics,  therapeutic use
Hospitalization / economics
Life Expectancy
Middle Aged
Models, Economic
Myocardial Infarction / drug therapy*,  mortality
Quality-Adjusted Life Years
Reg. No./Substance:
0/Enoxaparin; 0/Fibrinolytic Agents; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calc...
Next Document:  Quality of care for atrial fibrillation among patients hospitalized for heart failure.